ArticleFrontiers in medicine2025
High-sensitivity C-reactive protein and all-cause mortality in patients with diabetic foot and osteoporosis: evidence from a retrospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diabetic foot (DF), often accompanied by osteoporosis, greatly increases the risk of disability and death. Inflammation is a key driver, with high-sensitivity C-reactive protein (Hs-CRP) serving as a marker of low-grade systemic inflammation. Yet, its prognostic role in this population remains unclear. This study aimed to evaluate the association between Hs-CRP and all-cause mortality in patients with osteoporosis complicated by DF. Methods: This investigation was a single-center retrospective cohort study that enrolled 468 hospitalized patients with osteoporosis complicated by DF at the Affiliated Guangdong Second Provincial General Hospital of Jinan University between July 2020 and August 2025. Cox proportional hazards models, subgroup and sensitivity analyses were employed to examine the independent association between Hs-CRP and all-cause mortality. In addition, receiver operating characteristic (ROC) curves and restricted cubic spline (RCS) modeling were applied to assess the predictive performance of Hs-CRP and to explore potential dose-response relationships. Results: During a median follow-up of 38.4 months, a total of 50 deaths were recorded. Cox proportional hazards regression demonstrated a significant positive association between Hs-CRP and all-cause mortality. After full adjustment for potential confounders, each 1 mg/L increase in Hs-CRP was associated with a 1.6% higher risk of death (HR = 1.016, 95% CI: 1.004-1.027, Conclusion: Hs-CRP is independently associated with all-cause mortality in patients with osteoporosis complicated by DF, indicating its value for providing a potential tool for risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.